Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920

BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long‐term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases, the ongoing, multicohort phase 3b/4 CheckMate 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Emamekhoo, Hamid, Olsen, Mark R., Carthon, Bradley C., Drakaki, Alexandra, Percent, Ivor J., Molina, Ana M., Cho, Daniel C., Bendell, Johanna C., Gordan, Lucio N., Rezazadeh Kalebasty, Arash, George, Daniel J., Hutson, Thomas E., Arrowsmith, Edward R., Zhang, Joshua, Zoco, Jesus, Johansen, Jennifer L., Leung, David K., Tykodi, Scott S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298991/
https://www.ncbi.nlm.nih.gov/pubmed/34784056
http://dx.doi.org/10.1002/cncr.34016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298991/
https://www.ncbi.nlm.nih.gov/pubmed/34784056
http://dx.doi.org/10.1002/cncr.34016

Ejemplares similares